# A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer

> **NCT05076552** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Tachyon Therapeutics, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Solid Tumor
- Solid Tumor

## Interventions

- **DRUG:** TACH101

## Key facts

- **NCT ID:** NCT05076552
- **Lead sponsor:** Tachyon Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-17
- **Primary completion:** 2025-07
- **Final completion:** 2025-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05076552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05076552, "A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05076552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*